GFRAL–RET receptor complex antagonist (Cantius Therapeutics/University of Pennsylvania/Syracuse University)

N/A

Report date: 2025/06/11 10:42:05
NME

Base Information

Drug NameGFRAL–RET receptor complex antagonist (Cantius Therapeutics/University of Pennsylvania/Syracuse University)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitorsGDNF family receptor alpha-like antagonists
TargetsGDNF family receptor alpha-likeTyrosine-protein kinase receptor RET
Therapy Area/IndicationsChemotherapy-induced nausea and vomiting
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSyracuse University
China Registration ClassN/A

Develop Information

Active CompaniesSyracuse UniversityCantius Therapeutics LLCUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsChemotherapy-induced nausea and vomiting
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A